Evaxion A/S (EVAX) Competitors $2.83 +0.15 (+5.60%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$2.72 -0.11 (-3.92%) As of 08/6/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVAX vs. LPTX, NERV, EQ, ERNA, BFRG, ALVR, BIVI, FLGC, MTVA, and TXMDShould you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Leap Therapeutics (LPTX), Minerva Neurosciences (NERV), Equillium (EQ), Ernexa Therapeutics (ERNA), Bullfrog AI (BFRG), AlloVir (ALVR), BioVie (BIVI), Flora Growth (FLGC), MetaVia (MTVA), and TherapeuticsMD (TXMD). These companies are all part of the "pharmaceutical products" industry. Evaxion A/S vs. Its Competitors Leap Therapeutics Minerva Neurosciences Equillium Ernexa Therapeutics Bullfrog AI AlloVir BioVie Flora Growth MetaVia TherapeuticsMD Evaxion A/S (NASDAQ:EVAX) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Is EVAX or LPTX more profitable? Leap Therapeutics has a net margin of 0.00% compared to Evaxion A/S's net margin of -316.03%. Leap Therapeutics' return on equity of -162.15% beat Evaxion A/S's return on equity.Company Net Margins Return on Equity Return on Assets Evaxion A/S-316.03% -532.72% -78.32% Leap Therapeutics N/A -162.15%-120.05% Which has more risk & volatility, EVAX or LPTX? Evaxion A/S has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Do analysts recommend EVAX or LPTX? Evaxion A/S presently has a consensus target price of $10.00, suggesting a potential upside of 253.36%. Leap Therapeutics has a consensus target price of $3.38, suggesting a potential upside of 934.96%. Given Leap Therapeutics' higher probable upside, analysts clearly believe Leap Therapeutics is more favorable than Evaxion A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders believe in EVAX or LPTX? 11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 7.5% of Leap Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation and earnings, EVAX or LPTX? Evaxion A/S has higher revenue and earnings than Leap Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvaxion A/S$3.34M1.19-$10.57M-$1.16-2.44Leap TherapeuticsN/AN/A-$67.56M-$1.70-0.19 Does the media refer more to EVAX or LPTX? In the previous week, Evaxion A/S had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 1 mentions for Evaxion A/S and 0 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 0.00 beat Evaxion A/S's score of -0.10 indicating that Leap Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Evaxion A/S Neutral Leap Therapeutics Neutral SummaryEvaxion A/S beats Leap Therapeutics on 9 of the 15 factors compared between the two stocks. Get Evaxion A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVAX vs. The Competition Export to ExcelMetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.76M$2.02B$5.57B$9.47BDividend YieldN/AN/A4.31%4.13%P/E Ratio-2.4434.4629.3723.99Price / Sales1.199.98444.1896.63Price / CashN/A50.6235.8458.51Price / Book-2.408.718.085.58Net Income-$10.57M-$63.67M$3.26B$265.35M7 Day Performance5.60%-0.81%0.45%-0.07%1 Month Performance23.04%6.83%4.83%1.76%1 Year Performance-77.36%21.07%30.28%25.39% Evaxion A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVAXEvaxion A/S1.9741 of 5 stars$2.83+5.6%$10.00+253.4%-79.7%$3.76M$3.34M-2.4460Upcoming EarningsShort Interest ↑LPTXLeap Therapeutics1.8957 of 5 stars$0.34-5.6%$3.38+893.8%-84.8%$14.91MN/A-0.2040Upcoming EarningsGap DownNERVMinerva Neurosciences2.763 of 5 stars$2.10-1.4%$5.00+138.1%-38.1%$14.90MN/A2.569Positive NewsGap UpEQEquillium2.4771 of 5 stars$0.45+10.7%$3.00+573.2%-12.7%$14.38M$30.41M-1.1440Gap DownERNAErnexa Therapeutics0.8303 of 5 stars$1.91-2.1%N/A-93.3%$14.36M$580K-0.2310Upcoming EarningsBFRGBullfrog AI0.7679 of 5 stars$1.49-2.0%N/A-48.1%$14.31M$60K-1.844ALVRAlloVirN/A$2.76-2.8%N/A-85.4%$13.92MN/A-0.14110News CoverageUpcoming EarningsHigh Trading VolumeBIVIBioVie0.1782 of 5 stars$7.10-5.1%N/A-83.1%$13.91MN/A-0.0910FLGCFlora Growth2.8755 of 5 stars$0.61-1.5%$4.00+560.2%-48.7%$13.89M$59.51M-0.62280Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionMTVAMetaVia2.1845 of 5 stars$0.66-5.9%$7.50+1,030.4%N/A$13.81MN/A0.008News CoverageUpcoming EarningsTXMDTherapeuticsMD0.5873 of 5 stars$1.17-1.7%N/A-36.5%$13.77M$1.76M0.00420Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Leap Therapeutics Competitors Minerva Neurosciences Competitors Equillium Competitors Ernexa Therapeutics Competitors Bullfrog AI Competitors AlloVir Competitors BioVie Competitors Flora Growth Competitors MetaVia Competitors TherapeuticsMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVAX) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVAX Stock Alerts